scholarly journals Complete Response to Chemotherapy against the Recurrence of Neuroendocrine Carcinoma of the Breast in the Anterior Mediastinal Lymph Nodes of a Patient on Hemodialysis: A Case Report

2019 ◽  
Vol 12 (1) ◽  
pp. 205-210
Author(s):  
Emi Chikuie ◽  
Senichiro Yanagawa ◽  
Hidehiro Tanji ◽  
Shinya Kodama ◽  
Yukio Takeshima ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Chemotherapy Regimen ◽  
Mediastinal Lymph Node ◽  
Complete Response ◽  
Residual Renal Function ◽  
Carcinoma Of The Breast ◽  
Chemotherapy Administration ◽  
Response To Chemotherapy ◽  
Long Time ◽  
Anterior Mediastinal Lymph Nodes

In general, the cancer-bearing rate of patients on dialysis is considered to be higher than that of healthy individuals. There is no established chemotherapy regimen for patients on hemodialysis (HD), but some reports have described chemotherapy administration in such patients according to HD conditions, residual renal function, and the drug metabolic pathway. We present a case involving a 76-year-old female patient on HD who underwent chemotherapy for mediastinal lymph node recurrence of neuroendocrine carcinoma of the breast (NECB) using 5-fluorouracil, epirubicin, and cyclophosphamide (FEC 100) and docetaxel (DTX). The patient showed a complete response to the treatment and survived longer than expected. This is the first report demonstrating a complete response to chemotherapy for the recurrence of primary NECB with the patient having survived for a long time after treatment.

scholarly journals Case Report: A Rare Case of Esophagogastric Junctional Squamous Cell Carcinoma After the Successful Treatment of Neuroendocrine Carcinoma: Clonal Tumor Evolution Revealed by Genetic Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Hiroki Sato ◽  
Takeshi Saito ◽  
Hiroshi Horii ◽  
Mami Kajiura ◽  
Noriaki Kikuchi ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Cells ◽  
Somatic Mutation ◽  
Neuroendocrine Carcinoma ◽  
Squamous Cell ◽  
Complete Response ◽  
Tumor Evolution ◽  
Response To Chemotherapy ◽  
Eosinophilic Cytoplasm

Neuroendocrine carcinoma (NEC) of the esophagogastric junction (EGJ) is a rare disease with no established treatments. Herein, we describe a case of recurrent squamous cell carcinoma (SCC) after achieving complete response to chemotherapy against NEC of the EGJ. A 67-year-old man was referred to our hospital because of epigastric discomfort. Computed tomography imaging and esophagogastroduodenoscopy revealed ulcerated tumors at the EGJ. Endoscopic biopsy revealed small tumor cells with a high nuclear/cytoplasmic ratio, suggesting small-cell NEC. Immunohistochemistry (IHC) analysis showed tumor cells with an MIB-1 index of 80%. The patient achieved complete response after 10 cycles of chemotherapy. Follow-up endoscopic examination revealed small red-colored mucosal lesions in the center of the cicatrized primary lesion. Re-biopsy detected cancer cells harboring large eosinophilic cytoplasm with keratinization and no evidence of NEC components. IHC of the cells were cytokeratin 5/6-positive and p53-negative. The tumor persisted without evidence of metastases after chemoradiotherapy, and total gastrectomy with lymph node dissection was performed. Pathological assessment of the resected specimens revealed SCC, without evidence of NEC. The patient survived without a recurrence for >3 years after the initial presentation. Somatic mutation profiles of the primary NEC and recurrent SCC were analyzed by targeted amplicon sequencing covering common cancer-related mutations. Both tumors possessed TP53 Q192X mutation, whereas SMAD4 S517T was found only in SCC, suggesting that both tumor components originated from a founder clone with a stop-gain mutation in TP53. The somatic mutation profile of the tumors indicated that that loss of heterozygosity (LOH) at the TP53 gene might have occurred during the differentiation of the founder clone into NEC, while a SMAD4 mutation might have contributed to SCC development, indicating branching and subclonal evolution from common founder clone to both NEC and SCC. The mutation assessments provided valuable information to better understand the clonal evolution of metachronous cancers.

scholarly journals Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
João Lobo ◽  
Vera Constâncio ◽  
Pedro Leite-Silva ◽  
Rita Guimarães ◽  
Mariana Cantante ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Testicular Germ Cell Tumor ◽  
Complete Response ◽  
Differential Analysis ◽  
Testicular Germ Cell ◽  
Tissue Samples ◽  
Tumor Patient ◽  
Resistant Disease ◽  
Response To Chemotherapy

AbstractTesticular germ cell tumors (TGCTs) are among the most common solid malignancies in young-adult men, and currently most mortality is due to metastatic disease and emergence of resistance to cisplatin. There is some evidence that increased methylation is one mechanism behind this resistance, stemming from individual studies, but approaches based on matched primary and metastatic patient samples are lacking. Herein, we provide an EPIC array-based study of matched primary and metastatic TGCT samples. Histology was the major determinant of overall methylation pattern, but some clustering of samples related to response to cisplatin was observed. Further differential analysis of patients with the same histological subtype (embryonal carcinoma) disclosed a remarkable increase in net methylation levels (at both promoter and CpG site level) in the patient with cisplatin-resistant disease and poor outcome compared to the patient with complete response to chemotherapy. This further confirms the recent results of another study performed on isogenic clones of sensitive and resistant TGCT cell lines. Differentially methylated promoters among groups of samples were mostly not shared, disclosing heterogeneity in patient tissue samples. Finally, gene ontology analysis of cisplatin-resistant samples indicated enrichment of differentially hypermethylated promoters on pathways related to regulation of immune microenvironment, and enrichment of differentially hypomethylated promoters on pathways related to DNA/chromatin binding and regulation. This data supports not only the use of hypomethylating agents for targeting cisplatin-resistant disease, but also their use in combination with immunotherapies and chromatin remodelers.

Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Thomas A. Paterniti ◽  
Katie Dorr ◽  
Asad Ullah ◽  
Joseph White ◽  
Hadyn Williams ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Complete Response

Combination of mitotane and locoregional treatments in low-volume metastatic adrenocortical carcinoma

2021 ◽  
Author(s):  
Alice Boileve ◽  
Elise Mathy ◽  
Charles Roux ◽  
Matthieu Faron ◽  
Julien Hadoux ◽  
...  
Keyword(s):  
Adrenocortical Carcinoma ◽  
Stage Iv ◽  
Retrospective Chart Review ◽  
Progression Free Survival ◽  
Complete Response ◽  
Tumor Burden ◽  
Interquartile Range ◽  
First Line ◽  
Chemotherapy Administration ◽  
Metastatic Sites

Abstract Purpose European and French guidelines for ENSAT stage IV low tumor burden or indolent adrenocortical carcinoma (ACC) recommend combination of mitotane and locoregional treatments (LRT) in first-line. Nevertheless, the benefit of LRT combination with mitotane has never been evaluated in this selected group of patients. Methods A retrospective chart review was performed from 2003-2018 of patients with stage IV ACC with ≤2 tumoral organs who received mitotane in our center. Primary endpoint was the delay between mitotane initiation and first systemic chemotherapy. Secondary endpoints were progression-free survival (PFS) and overall survival (OS) from mitotane initiation. Adjusted analyses were performed on the main prognostic factors. Results Out of 79 included patients, 48 (61%) patients were female and median age at stage IVA diagnosis was 49.8 years (interquartile-range:38.8-60.0). Metastatic sites were mainly lungs (76%) and liver (48%). Fifty-eight (73%) patients received LRT including adrenal bed radiotherapy (14 patients, 18%), surgery (37 patients, 47%) and/or interventional radiology n(35,44%). Median time between mitotane initiation and first chemotherapy administration was 9 months (Interquartile-range:4-18). Median PFS1 (first tumor-progression) was 6.0 months (CI95%:4.5-8.6). Median OS was 46 months (CI95%:41-68). PFS1, PFS2 and OS were statistically longer in the mitotane plus LRT group compared to the mitotane-only group (Hazard ratio (HR)=0.39 (CI95%:0.22-0.68), HR=0.35 (CI95%:0.20-0.63) and HR=0.27 (CI95%:0.14-0.50) respectively). Ten (13%) patients achieved complete response, all from mitotane plus LRT group. Conclusion Our results endorse European and French guidelines for stage IV ACC with ≤2 tumor-organs and favor the combination of mitotane and LRT as first-line treatment. For the first time, a significant number of complete responses were observed. Prospective studies are expected to confirm these findings.

Complete Response to Chemotherapy in Intra-Abdominal Desmoplastic Small round Cell Carcinoma. A Case Report

1998 ◽  
Vol 84 (3) ◽  
pp. 412-416 ◽  
Author(s):  
Mario De Lena ◽  
Maria Lucia Caruso ◽  
Franco Marzullo ◽  
Sergio Mancarella ◽  
Raffaele Armentano ◽  
...  
Keyword(s):  
Good Health ◽  
Complete Response ◽  
Complete Disappearance ◽  
Round Cell ◽  
Small Round Cell ◽  
Response To Chemotherapy ◽  
Lower Abdominal Quadrant ◽  
Antineoplastic Treatment ◽  
Multiagent Chemotherapy ◽  
The Right

Aims and background The authors report the case of a 23-year-old woman affected by intra-abdominal desmoplastic small round cell tumor (DSRCT) who obtained a complete response to multiagent chemotherapy. DSRCT is a rare, highly aggressive neoplasm generally arising in young people and seldom in females (about 20 cases described in the literature). Methods The patient underwent surgical resection of a large 15 × 15 cm mass located in the right lower abdominal quadrant, but after only 2 months later, two liver metastasis were noted. Thus, she was subjected to an aggressive antineoplastic treatment consisting of three groups of alternating non-cross resistant multiagent regimens administered every 21 days (cis-platin-etoposide-adriamycin-bleomicin; gemcitabine-ifosfamide-dacarbazine; methotrexate-5-fluorouracilfolinic acid) for a total of 9 administrations. Results After one cycle of treatment including the administration of all the three alternated schemes of chemotherapy, a complete disappearance of liver disease was noted. The treatment was relatively well-tolerated and the toxicity was acceptable. At present, after 15 months from diagnosis and 12 months after starting chemotherapy, the patient is disease-free and in good health. Conclusions Even though this study regards only a single patient, it is noteworthy because of the rarity of this neoplasm and because of the infrequent complete responses reported in the literature. The efficacy and manageability of the treatment, suggests that both the timing and schedule used could constitute an important therapeutical option for this aggressive and poorly chemo-responsive tumor.

Fine needle aspiration cytology of solid neuroendocrine carcinoma of the breast: A case report

2010 ◽  
Vol 39 (7) ◽  
pp. 527-530 ◽  
Author(s):  
Namiki Kawanishi ◽  
Yoshiaki Norimatsu ◽  
Mahito Funakoshi ◽  
Toshiaki Kamei ◽  
Hiroshi Sonobe ◽  
...  
Keyword(s):  
Case Report ◽  
Neuroendocrine Carcinoma ◽  
Fine Needle Aspiration ◽  
Fine Needle Aspiration Cytology ◽  
Needle Aspiration ◽  
Carcinoma Of The Breast ◽  
Aspiration Cytology ◽  
Fine Needle ◽  
Needle Aspiration Cytology

scholarly journals NEUROENDOCRINE CARCINOMA OF THE BREAST: 18 CASES WITH LONG-TERM FOLLOW-UP

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Enver Özkurt ◽  
Mehmet İlhan ◽  
Ömer Cücük ◽  
Mustafa Tükenmez ◽  
Neslihan Cabioğlu ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Carcinoma Of The Breast ◽  
Long Term Follow Up

scholarly journals PRIMARY NEUROENDOCRINE CARCINOMA OF THE BREAST: A RARE ENTITY

2020 ◽  
Vol 06 (01) ◽  
pp. 33-34
Author(s):  
Aravinth Subramaniam ◽  
Divya Gnanasekaran ◽  
Saravanakumar Suruliraj ◽  
Palanivelu Chinnusamy
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Rare Entity ◽  
Carcinoma Of The Breast

scholarly journals Nomogram predicted overall survival of patients with neuroendocrine carcinoma of the breast

2020 ◽  
Author(s):  
Wenwen Tian ◽  
Xinhua Xie ◽  
Yanan Kong ◽  
Peng Liu ◽  
Weige Tan ◽  
...  
Keyword(s):  
Overall Survival ◽  
Neuroendocrine Carcinoma ◽  
Operating Characteristic ◽  
Roc Curves ◽  
Population Based ◽  
Cancer Center ◽  
Breast Cancers ◽  
Seer Database ◽  
Carcinoma Of The Breast ◽  
N Stage

Abstract Background For primary neuroendocrine carcinoma of breast was a very rare subtype in breast cancers, its prognosis was still controversial and there was no independent standard for its treatment. The purpose of our retrospective study was to construct a nomogram to predict the overall survival (OS) of patients with neuroendocrine carcinoma of the breast. Methods 150 patients of training cohort were collected from Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2003 and 2015, and 93 patients of verification cohort were enrolled from Sun Yat-sen University Cancer Center (Guangzhou, China) diagnosed between 2004 and 2018. The nomogram was constructed uniting three significantly risk factors of overall survival identified by univariate and multivariate analysis and then validated using receiver operating characteristic (ROC) curves for discrimination, calibration plots and the decision curves analysis (DCA). Results Age, N stage and PR status were closely and significantly related to overall survival in patients with breast neuroendocrine carcinoma. The C-index of nomogram in the training and verification cohorts are 0.775 (95% CI, 0.784 to 0.615) and 0.760 (95% CI, 0.705 to 0.800) respectively. Calibration plots of practical and predicted possibility for the nomogram demonstrated that the predictive 5-year overall survival rate was in accordance with the actual overall survival probability in both sets. Moreover, the decision curves (DCA) also expressed pretty clinical benefit of the nomogram across a range of high-risk threshold. Conclusion This novel population-based nomogram may help with treatment decisions in patients with neuroendocrine carcinoma of the breast (NEBC).

Sign in / Sign up

Export Citation Format

Share Document